Two recent available therapeutic strategies are able to enhance the prognosis for patients with melanoma [5], which are the introduction of immune-checkpoint inhibitors in cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) enabling a reactivation of the immune responses against cancer [5,7]. The gene discussed is CTLA4; the disease is melanoma.